Royalty Pharma (MEX:RPRX) YoY EBITDA Growth : 1,490.18% (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Royalty Pharma YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Royalty Pharma's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was 1,490.18%.

Royalty Pharma's EBITDA per Share for the three months ended in Mar. 2025 was MXN17.65.

Royalty Pharma YoY EBITDA Growth Historical Data

The historical data trend for Royalty Pharma's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma YoY EBITDA Growth Chart

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

Get a 7-Day Free Trial

-32.00

-29.06

-73.34

181.73

2.82

Royalty Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
YoY EBITDA Growth	Get a 7-Day Free Trial															-93.27	-33.72	495.28	-34.85	1,490.18

Royalty Pharma YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Royalty Pharma's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(54.634	-	53.135)	/	\| 53.135 \|
=	2.82 %

Royalty Pharma's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2025 )
=	(EBITDA per Share (Q: Mar. 2025 )	-	EBITDA per Share (Q: Mar. 2024 ))	/	\| EBITDA per Share (Q: Mar. 2024 )) \|
=	(17.651	-	1.11)	/	\| 1.11 \|
=	1,490.18 %

Royalty Pharma YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (MEX:RPRX) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

RPRX:USA RPD:Germany

Address

110 East 59th Street, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.